Nasdaq:US$16.62 (-1.04) | HKEX:HK$26.65 (-1.55) | AIM:£2.68 (-0.19)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer